Abel EL. (1980). Marihuana: The First Twelve Thousand Years. New York: McGraw-Hill.
Abrahamov A, Abrahamov A, Mechoulam R. (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 56(23–24):2097–2102.
Abrams D. (2010). Cannabinoid: Opioid Reactions. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.
Abrams D. (2002). Cannabis use with AIDS patients. Presentation at The Second National Clinical Conference on Cannabis Therapeutics, May 3, 2002; co-sponsored by Patients Out of Time and the Oregon Department of Human Services, Health Services; held at the Holiday Inn, Portland, OR.
Abrams DI, Hilton JF, Leiser RJ, et al. (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Annals of Internal Medicine 139: 258–66.
Aldrich M. (1997). History of therapeutic cannabis. In ML Mathre (Ed.), Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (pp. 35–55). Jefferson, NC: McFarland.
American College of Obstetricians and Gynecologists (ACOG). (2017, October). ACOG Committee Opinion No. 722. Marijuana Use During Pregnancy and Lactation. (Replaces Committee Opinion No. 637, July 2015). Obstetrics & Gynecology 130:e205-209.
American Nurses Association (ANA), Center for Human Rights. (2016). Therapeutic Use of Marijuana and Related Cannabinoids. Revised Position Statement. Retrieved August 9, 2019 from https://www.nursingworld.org/~49a8c8/globalassets/practiceandpolicy/ethics/therapeutic-use-of-marijuana-and-related-cannabinoids-position-statement.pdf.
Anthony LC, Warner LA, Kessler RC. (1994). Comparative Epidemiology of Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants: Basic Findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology 2(3):244–68. Retrieved August 9, 2019 from http://www.biblioteca.cij.gob.mx/articulos/PatronDeUsoYDependencia/1999.
Appendino G, Gibbons S, Giana A, et al. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. Journal of Natural Products 71:1427–30.
Bachhuber, MA, Saloner B, Cunningham, CO, Barry, CL (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Internal Medicine 174(10:1668–73.
Bender B. (May 20, 2017). American Legion to Trump: Allow marijuana research for vets—Under current rules, doctors with the Department of Veterans Affairs cannot even discuss marijuana as an option with patients, Politico. Retrieved June 22, 2019 from https://www.politico.com/story/2017/05/20/veterans-marijuana-trump-american-legion-238626.
Blanco C, Hasin DS, Wall MM, Florez-Salamanca L, et al. (2016). Cannabis use and risk of psychiatric disorders: Prospective evidence from a US National Longitudinal Study. JAMA Psychiatry 73: 388–95.
Blumgartin AS. (1919). Materia Medica for Nurses, 2nd Ed. New York: MacMillan.
Bonnie RJ, Whitebread II. (CH). (1974). The Marihuana Conviction: A History of Marihuana Prohibition in the United States. Charlottesville: University Press of Virginia.
Broyd SJ, et al. (2016). Acute and chronic effects of cannabinoids on human cognition—A systematic review. Biol Psychiatry 79(7):557-67.
Cabral GA, Rogers TJ, Lichtman, AH. (2015). Turning over a new leaf: Cannabinoid and endocannabinoid modulation of immune function. J Neuroimmune Pharmacol 10:193–203. DOI 10.1007/s11481-015-9615-z.
Californian, The. (2017, July 17). DEA hasn’t loosened marijuana cultivation monopoly while applications from researchers mount. Brooke Edwards Staggs. Retrieved August 9, 2019 from http://www.thecannifornian.com/cannabis-health/research-studies/dea-hasnt-loosened-marijuana-cultivation-monopoly-applications-researchers-mount/.
Centers for Disease Control (CDC). National Center for Chronic Disease Prevention and Health Promotion. (2018a). Marijuana Fact Sheet: What You Need to Know About Marijuana Use and Pregnancy. Retrieved April 30, 2019 from https://www.cdc.gov/marijuana/pdf/Marijuana-Pregnancy-H.pdf.
Center for Disease Control (CDC). (2018b). National Center for Chronic Disease Prevention and Health Promotion. Marijuana Fact Sheet: What You Need to Know About Marijuana Use in Teens. Retrieved April 30, 2019 from https://www.cdc.gov/marijuana/pdf/Marijuana-Teens-H.pdf.
Chan PC, Sills RC, Braun AG, et al. (1996). Toxicity and carcinogenicity of delta-9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundamental and Applied Toxicology 30(1):109–17.
Children’s Hospital Colorado. (2019). Medical Marijuana and Its Use at Children's Hospital Colorado. Retrieved August 9, 2019 from https://www.childrenscolorado.org/conditions-and-advice/marijuana-what-parents-need-to-know/medical-marijuana/use-at-children-s-hospital-colorado/.
Colorado Department of Public Health and Environment. (2018). Monitoring Health Concerns Related to Marijuana in Colorado: 2018—Summary.
Colorado Department of Public Health and Environment. (2019). Colorado Medical Marijuana Registry Program Statistics: May 2019. Retrieved June 21, 2019 from www.colorado.gov/cdphe/medicalmarijuana.
Compton, R. (2017, July). Marijuana-Impaired Driving—A Report to Congress. (DOT HS 812 440). Washington, DC: National Highway Traffic Safety Administration.
Cone EJ, Bigelow GE, Herrmann ES, et al. Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results. J Anal Toxicol. 2015;39(1):1-12. Doi:10.1093/jat/bku116.
Conner SN, Bedell V, Lipsey K, et al. (2016, October). Maternal marijuana use and adverse neonatal outcomes: A systematic review and meta-analysis. Obstet Gynecol. 128(4):713-23. Doi: 10.1097/AOG.0000000000001649. Retrieved June 1, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/27607879.
Controlled Substances Act, The (CSA). (1970). The Act. Retrieved August 9, 2019 from Title 21 United States Code (USC) Controlled Substances Act.
Craker L. (2010). Chasing the rainbow: Medical cannabis and the struggle to break the NIDA monopoly. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.
Crippa J. (2010). Cannabidiol for the treatment of neuropsychiatric disorders: Past, present and future. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.
Cushing R. (March 29, 2001). Pot Shrinks Tumors; Government Knew in ’74. San Antonio Current, TX.
Democratic Platform Committee. (2016). 2016 Democratic Party Platform. Approved July 8–9, 2016, Orlando, FL. Retrieved June 22, 2019 from https://www.demconvention.com/wp-content/uploads/2016/07/Democratic-Party-Platform-7.21.16-no-lines.pdf.
Devane WA, Dysarz FA III, Johnson MR, et al. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34:605–13.
Devane WA, Hanus L, Breuer A, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–49.
Di Marzo V, Melck D, Bisogno T, De Petrocellis L. (1998). Endocannabinoids: Endogenous cannabinoid receptor ligands with neruomodulatory action. Trends in Neuroscienc. 21:521–28O
Diagnostic and Statistical Manual of Mental Disorders (DSM-V). (2013).
Dowell D, Haegerich TM, Chou R. (2016). CDC Guidelines for Prescribing Opioids for Chronic Pain, United States 2016. MMWR Recomm Rep 2016;65:1–49. DOI: http://dx.doi.org/10.15585/mmwr.rr6501e1.
Dreher M. (1997). Cannabis and pregnancy. In ML Mathre (Ed.), Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana (pp. 159–70). Jefferson, NC: McFarland.
Edney A. (2014). DEA requested to remove marijuana from Schedule !. Retrieved August 9, 2019 from https://en.wikipedia.org/wiki/Removal_of_cannabis_from_Schedule_I_of_the_Controlled_Substances_Act
Edwards Staggs B. (2017, July 2). DEA hasn’t loosened marijuana cultivation monopoly while applications from researchers mount. The Cannifornian. Retrieved July 4, 2019 from http://www.thecannifornian.com/cannabis-health/research-studies/dea-hasnt-loosened-marijuana-cultivation-monopoly-applications-researchers-mount/.
Federal Drug Administration (FDA). (2019). FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers. Retrieved August 9, 2019 from https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questions-and-answers.
Freimuth N, Ramer R, Burkhard H. (2010). Anti-tumorigenic effects of cannabinoids beyond apoptosis. Perspectives in Pharmacology 332(2):336–44.
Fride E, Bregman T, Kirkham TC. (2005). Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. (Review). Exp Biol Med (Maywood) 230(4):225–34.
Frisher M, Crome I, Martino O, Croft P. (2009). Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. Schizophr Res 113(2-3):123.
Grotenhermen F. (2007). The toxicology of cannabis and cannabis prohibition. Chemistry and Biodiversity 4:1744–69.
Grotenhermen F. (2005). Cannabinoids. Current Drug Targets—CNS and Neurological Disorders 4:507–30.
Grotenhermen F, Russo E. (Eds.) (2002). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. NY: Haworth Integrative Healing Press.
Grucza RA, Agrawal A, Krauss MJ, et al. (2016). Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry 73(3):300–301.
Gurney J, Shaw C, Stanley J, et al. (2015). Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer 15, Article number: 897. Retrieved August 9, 2019 from https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1905-6.
Hall W, Room R, Bondy S. (1999). Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In: Kalant H, et al, eds, The Health Effects of Cannabis, pp. 477–508. Toronto: Addiction Research Foundation.
Hampson AJ, Axelrod J, Grimaldi M. (2003). Cannabinoids as Antioxidants and Neuroprotectants. Patent No. US 6,630,507 B1. Date: 10/7/2003. U.S. Patent and Trademark Office.
Harvard Health Publishing. (2019). Marijuana and heart health: What you need to know. Published August 2017, updated June 24, 2019. Retrieved June 29, 2019 from https://www.health.harvard.edu/heart-health/marijuana-and-heart-health-what-you-need-to-know.
Hashibe M, Morgenstern H, Cui Y, et al. (2006). Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case-controlled study. Cancer Epidemiological Biomarkers Prevention 15(10):1829–34.
Hasse J. Federal Appeals Court Rules DEA, Federal Govt. Must 'Promptly' Reassess Marijuana's Illegality. Forbes. Retrieved June 22, 2019 from https://www.forbes.com/sites/javierhasse/2019/05/31/federal-appeals-court-rules-dea-federal-govt-must-promptly-reassess-marijuanas-illegality/#5e78d8767be9.
Henningfield JE, Benowitz NL. (1994, August 2). In Hilts PJ: Is Nicotine Addictive? It Depends of the Criteria You Use. Cited in The New York Times (p. C3).
Herzode C, Roudot-Thoraval F, Nguyen S, et al. (2005). Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology 42(1):63–71.
Holland J. (Ed.). (2010). The Pot Book: A Complete Guide to Cannabis. Rochester, VT: Park Street Press.
Hyatbakhsh M, Flenady V, Gibbons K, et al. (2013). Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res 71:215–19.
Izzo AA, Borrelli F, Capasso R, et al. (2009). Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences 30(10):515–27.
Johnson RM, LaValley KE, Schneider RJ, et al. (2017, May 1). Marijuana use and physical dating violence among adolescents and emerging adults: A systematic review and meta-analysis. Drug and Alcohol Dependence 174: 47–57. Retrieved August 9, 2019 from https://doi.org/10.1016/j.drugalcdep.2017.01.012.
Joy JE, Watson SJ, Benson JA. (1999). Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press (Institute of Medicine). ISBN 0-309-07155-0.
Kogan NM, Mechoulam R. (2007). Cannabinoids in health and disease. Dialogues Clin Neurosci. 9(4):413–30. Retrieved August 9, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/18286801.
Lucas P. (2004). British Columbia Patient Surveys. Presentation at The Third National Clinical Conference on Cannabis Therapeutics, May 22, 2004; co-sponsored by Patients Out of Time and the University of Virginia Schools of Medicine, Nursing, and Law; held at the Omni Hotel, Charlottesville, VA.
Lopez G. (2014, May 30). The House just voted to protect medical marijuana patients from federal interference. Vox. https://www.vox.com/2014/5/30/5763654/the-house-just-voted-to-protect-medical-marijuana-patients-from. Accessed: 6/22/2019.
Macleod J, Davey Smith G, Hickman M. (2006). Does cannabis use cause schizophrenia? Lancet 367(9516):1055.
Marijuana Health Monitoring and Research Program (MHMRP), Colorado Department of Public Health and Environment. (2018). Monitoring Health Concerns Related to Marijuana in Colorado: 2018 Summary. Retrieved June 1, 2019, from https://www.colorado.gov/pacific/marijuanahealthinfo/summary.
Martin M, Rosenthal E, Carter G. (2011). Medical Marijuana 101. Quick American Publishing: Oakland, CA.
Mathre ML. (1985). Marijuana Disclosure to Health Care Professionals. Unpublished master’s thesis. Case Western Reserve University, Cleveland, Ohio.
McPartland J. (2008). The endocannabinoid system: An osteopathic perspective. JAOA 108(10):586–600.
McPartland JM, Russo EB. (2001). Cannabis and cannabis extracts: Greater than the sum of their parts? Journal of Cannabis Therapeutics 1(3–4), 103–32.
Mechoulam R. (2010a). Head trauma, osteoporosis, and Alzheimer’s disease—an unexpected trio. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.
Mechoulam R. (2010b). Cannabis: Opening new vistas in both therapy and chemical biology. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 16, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.
Melamede R. (2006). Cannabinoids and the Physics of Life. Presentation at The Fourth National Clinical Conference on Cannabis Therapeutics, April 7, 2006; co-sponsored by Patients Out of Time and UCSF School of Medicine; held at Santa Barbara City College, Santa Barbara, CA.
Munro S, Thomas KL, Abu-Shaar M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature (London). 365:61–65.
Munson AE, Harris LS, Friedman MA, et al. (1975). Antineoplastic activity of cannabinoids. Journal of the National Cancer Institute 55(3): 597–602.
Nassan FL, Arvizu M, Mínguez-Alarcón L, et al. (2019, February 6). Marijuana smoking and markers of testicular function among men from a fertility centre. Human Reproduction 34(4):715–723. Retrieved June 29, 2019 from https://doi.org/10.1093/humrep/dez002.
National Academies. (2017, January 12). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. DOI: https://doi.org/10.17226/24625. Retrieved August 9 2019 from https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state.
National Commission on Marihuana and Drug Abuse. (1972). Marihuana: A Signal of Misunderstanding. New York: New American Library.
National Institutes of Health (NIH). (2016). Marijuana and Cannabinoids: A Neuroscience Research Summit—Meeting Summary. National Institutes of Health Natcher Conference Center, Bethesda, Maryland. March 22–23, 2016. https://www.drugabuse.gov/sites/default/files/briefmjsummitmeetingsummary.pdf. Accessed: 5/28/2019.
National Institutes of Health (NIH). (2018). NIH Research on Marijuana and Cannabinoids. Revised May 2018. Retrieved June 22, 2019 from https://www.drugabuse.gov/drugs-abuse/marijuana/nih-research-marijuana-cannabinoids.
National Institute on Drug Abuse (NIDA). (2019). Drug Facts. Drugged Driving. Revised March 2019. Retrieved June 10, 2019 from https://www.drugabuse.gov/publications/drugfacts/drugged-driving. Accessed 6/10/2019.
National Institute on Drug Abuse (NIDA). (2018). What Are Marijuana’s Long-Term Effects on the Brain? Page last updated June 2018. Retrieved June 9, 2019 from https://www.drugabuse.gov/publications/research-reports/marijuana/what-are-marijuanas-long-term-effects-brain.
National Institute on Drug Abuse (NIDA). (2016). Researching the Potential Medical Benefits and Risks of Marijuana. July 13, 2016. Presentation by Susan R.B. Weiss, PhD, Director, Division of Extramural Research to the
Senate Judiciary Committee, Subcommittee on Crime and Terrorism. https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2016/researching-potential-medical-benefits-risks-marijuana. Accessed: 4/30/2019.
Nielsen S, P. Sabioni JM, Trigo MA, et al. (2017, August). Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis. Neuropsychopharmacology 42(9):1752–65. Doi: 10.1038/npp.2017.51 PMCID: PMC5520783 PMID: 28327548.
New Mexico Department of Health. (2016). New Mexico Medical Cannabis Program Patient Statistics ,November 2016. Retrieved June 21, 2019 from https://nmhealth.org/publication/view/report/3241/. Accessed 6/21/19.
Oregon Health Authority. (2019). Oregon Medical Marijuana Program Statistics. Retrieved June 21, 2019 from https://www.oregon.gov/oha/PH/DISEASESCONDITIONS/CHRONICDISEASE/MEDICALMARIJUANAPROGRAM/Documents/OMMP%20Statistic%20Snapshot%20-%2004-2019.pdf.
Owen KP, Sutter ME, Albertson TE. (2014). Marijuana: Respiratory tract effects. Clin Rev Allergy Immunol. 46(1):65-81. Doi:10.1007/s12016-013-8374-y.
Pacher P, Bátkai S, Kunos G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58(3):389–462.
Pasquariello A. (2017, July 25). Federal lawsuit against Sessions and DEA says marijuana's Schedule I status unconstitutional. The Cannabist, The Denver Post. Retrieved July 4, 2019 from https://www.thecannabist.co/2017/07/25/marijuana-schedule-i-lawsuit-unconstitutional/84473/.
Pertwee R (Ed.) (2014). Handbook of Cannabis. Oxford: Oxford University Press.
Plasse T. (2002). Antiemetic effects of cannabinoids. In: Grotenhermen, F., and Russo E. (Eds.), Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential (pp. 165–80). New York: Haworth Integrative Healing Press.
Radhakrishnan R, Wilkinson ST, D'Souza DC . (2014, May 22). Gone to pot—A review of the association between cannabis and psychosis. Front Psychiatry 5:54. Doi: 10.3389/fpsyt.2014.00054.
Randall R. (Ed.). (1988). Marijuana, Medicine, and the Law. Washington, DC: Galen Press.
Randall R, O’Leary A. (1998). Marijuana Rx: The Patients’ Fight for Medicinal Pot. New York: Thunder’s Mouth Press.
Reece-Stremtan S, Marinelli KA, and The Academy of Breastfeeding Medicine. (2015). ABM Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, Revised 2015. Breastfeeding Medicine 10(3). Mary Ann Liebert, Inc. DOI: 10.1089/bfm.2015.9992.
Reiman A. (2008). Compassion Clubs of California. Presented at The Fifth National Clinical Conference on Cannabis Therapeutics, April 5, 2008; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at Asilomar Conference Grounds, Pacific Grove, CA.
Reingle JM, Staras SAS, Jennings WG, et al. (2012, May). The Relationship Between Marijuana Use and Intimate Partner Violence in a Nationally Representative, Longitudinal Sample. J Interpers Violence 27(8):1562–78. Doi: 10.1177/0886260511425787.
Rhode Island Department of Health. (2017). Medical Marijuana Program Patients by Diagnosis in Rhode Island, 2013. Retrieved July 29, 2019 from http://www.health.ri.gov/publications/programreports/MedicalMarijuana2013.pdf.
Richmond L. (Writer, Director). (2010). What if Cannabis Cured Cancer (DVD). Len Richmond Films.
Rumalla K, Reddy AY, Mittal MK. (2016). Recreational marijuana use and acute ischemic stroke: A population-based analysis of hospitalized patients in the United States. Journal of Neurological Sciences 364:191–96.
Russo EB, Guy GW, Robson PJ. (2007). Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chemistry and Biodiversity 4:1729–43.
Russo E. (2004). Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome, and other treatment-resistant conditions? Neuroendocrinology Letters 25(1–2): 31–39.
Schnelle M, Strasser F. (2002) Anorexia and cachexia. In: F. Grotenhermen and E. Russo (Eds.), Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential (pp. 153–64). New York: Haworth Integrative Healing Press.
Sidney S, Beck JE, Tekawa IS, et al. (1997). Marijuana use and mortality. American Journal of Public Health 87(4):585–90.
Sylvestor D, et al. (2006). Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology and Hepatology 18:1057–63.
Takahashi R. (2010). Cannabinoids and adverse memories in animals: Novel perspectives in the treatment of PRS(d). Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 17, 2010; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at the Crowne Plaza Hotel, Warwick, RI.
Tashkin DP. (2008). Does Regular Marijuana Smoking Lead to Pulmonary or Pulmonary-Related Disease (COPD, Lung Cancer, Pneumonia)?: Cohort- and Population-based Studies. Presented at The Fifth National Clinical Conference on Cannabis Therapeutics, April 4, 2008; co-sponsored by Patients Out of Time and the UCSF School of Medicine; held at Asilomar Conference Grounds, Pacific Grove, CA.
Tashkin DP. (2013, June). Effects of Marijuana Smoking on the Lung. Annals American Thoracic Society 10(3). Retrieved June 9, 2019, from https://doi.org/10.1513/AnnalsATS.201212-127FR.
Teaganne F, Wasson E, Flatley D. (2018, November 29). Lawmakers Reach Farm Bill Deal by Dumping GOP Food-Stamp Rules. Retrieved June 22, 2019 from https://www.bloomberg.com/news/articles/2018-11-29/farm-bill-deal-reached-by-dumping-new-work-rules-backed-by-trump.
Teesson M, Lynskey M, Manor B, Baillie A. (2002). The structure of cannabis dependence in the community. Drug and Alcohol Dependence 68:255–62.
United States Congress. (1970). Controlled Substances Act (P.L. 91-513, 84 Stat. 1242). Retrieved June 29, 2011 from http://www.enotes.com/major-acts-congress/controlled-substances-act.
U.S. Food and Drug Administration (FDA). (2019, April 2). FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers. Retrieved June 1, 2019 from https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questions-and-answers.
Velasco G, Sanchez C, Guzman M. (2012, May 4). Towards the use of cannabinoids as anti-
tumour agents. Nature Reviews Cancer. Online 4 May 2012; doi:10.1038/nrc3247.
Washington Post. (2017, October 16). Amid opioid crisis, 2016 law derails DEA’s enforcement abilities. By Scott Higham and Lenny Bernstein. Retrieved from https://www.twincities.com/2017/10/16/amid-opioid-crisis-2016-law-derails-dea/.
Weil A, Rosen W. (1993). From Chocolate to Morphine: Everything You Need to Know About Mind-Altering Drugs. Boston: Houghton Mifflin.
West M. (1997). The use of certain cannabis derivatives (Canasol) in glaucoma. In ML Mathre (Ed.), Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (pp.103–11). Jefferson, NC: McFarland.
Wolff V, Armspach JP, Lauer V, et al. 2013. Cannabis-related stroke: Myth or reality? Stroke 44(2):558–563. Retrieved July 4, 2019 from https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.112.671347.
Wu T-C, Tashkin DP, Djahed B, Rose JE. (1988). Pulmonary hazards of smoking marijuana as compared with tobacco. New England Journal of Medicine 318(6):347–51.
Young FL, and U.S. Department of Justice, Drug Enforcement Administration (DOJ/DEA). (1988, September 6). In the Matter of Marijuana Rescheduling Petition (Docket No. 86-22). Opinion and Recommended Ruling, Findings of Fact, Conclusions of Law and Decision of the administrative law judge Francis L. Young.
Zimmer L, Morgan JP. (1997). Marijuana Myths, Marijuana Facts. New York: The Lindesmith Center.